-

Canary Capital Updates Staked Injective ETF: INJ Price Rally Ahead?
Canary Capital has amended its staked Injective ETF filing with the SEC, sparking a 5% INJ price rebound. Discover what changed in the prospectus, why investors are excited, and what the approval timeline could look like.
-

21Shares Injective ETF: SEC Reviews Amended Filing
The SEC has received an amended S-1/A filing from 21Shares for its proposed Injective (INJ) ETF, signaling continued momentum in the altcoin ETF race. The move could accelerate institutional adoption and reshape how investors access mid-cap crypto assets.